Track PURE Bioscience's receivables ($240K) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
The latest receivables for PURE is $240K as of April 2026. That compares with $290K in the prior-year period — down 15.7% year over year. Investors often review this figure alongside PURE Bioscience's historical trend and sector peers before judging valuation or financial health.
Over the past year, PURE's receivables moved from $290K to $240K — a 15.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in PURE Bioscience's operating scale or balance-sheet position.
A receivables figure of $240K for PURE is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.
After noting PURE's receivables ($240K), review year-over-year change from $290K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.